Collectively, these data indicate that DLK1 is a potential prognostic factor for AML patient OS and the tumor-suppressing abilities of MEG3 may be overwhelmed by DLK1 expression and/or CpG site-specific signatures of its downstream miRNAs [33]. This evidence concerns the gene MEG3 and neoplasm.